The 69.4% gross margin in 2026Q2, up from 47.8% in 2024Q1, indicates that ADMA's product mix is increasingly weighted toward high-margin ASCENIV, which appears to be the primary profit engine. Operating margin expanded to 42.2% in 2026Q2 from 26.7% in 2024Q1, reflecting operating leverage as SG&A grew slower than revenue. However, the 2024Q4 net margin spike to 95.2% was driven by a one-time tax benefit, so the 30.4% net margin in 2026Q2 is a more sustainable baseline, though investors should monitor plasma cost volatility and batch timing.

ROIC has trended upward from 6.9% in 2024Q1 to 8.4% in 2026Q2, though it remains below the 12.0% peak in 2024Q2, suggesting that recent debt-financed buybacks have expanded the capital base. The improvement is driven primarily by margin expansion rather than asset turnover, which has declined from 0.31 in 2024Q3 to 0.18 in 2026Q2, reflecting the long plasma manufacturing cycle. ROE of 9.5% in 2026Q2 is modest but improving, and the trajectory suggests that ADMA is compounding returns as it scales its specialty plasma model.

The CCC lengthened from 276 days in 2024Q3 to 589 days in 2026Q2, primarily due to DIO rising from 269 to 551 days, which reflects the 6-12 month manufacturing cycle for plasma-derived products. DSO also increased from 31 to 100 days over the same period, suggesting slower collections or a change in payer mix, while DPO rose from 23 to 62 days, indicating some supplier leverage. This working capital intensity explains the gap between net income and operating cash flow, and investors should monitor whether inventory builds are strategic or indicative of demand softness.

ADMA's D/E rose from 0.17 in 2025Q4 to 0.50 in 2026Q2, driven by $203.8M in total debt, which appears to have funded $130.2M in buybacks in 2026Q1. Despite the increase, interest coverage remains comfortable at 15.67 in 2026Q2, down from 38.88 in 2025Q4 but still well above the 5.88 level in 2024Q1. The leverage increase is notable but appears manageable given the company's strong margins and cash flow, though investors should monitor whether further debt-financed buybacks could strain the balance sheet.

The current ratio of 6.97 in 2026Q2, down from 7.13 in 2025Q3 but still high, indicates that ADMA has ample short-term assets to cover liabilities, even with inventory days at 551. Quick ratio of 3.81 suggests that even excluding inventory, liquidity is strong, though the inventory-heavy balance sheet means that a write-down could impact the current ratio. The $136.0M cash position, combined with positive FCF, suggests that ADMA can fund its operations and capital expenditures without near-term liquidity stress.